Antioxidant activity of carvedilol in cardiovascular disease

被引:140
作者
Dandona, Paresh
Ghanim, Husam
Brooks, David P.
机构
[1] SUNY Buffalo, Diabet Endocrinol Ctr Western New York, Div Endocrinol Diabet & Metab, Buffalo, NY 14209 USA
[2] Kaleida Hlth, Buffalo, NY USA
[3] GlaxoSmithKline, Cardiovasc & Urogenital Ctr Excellence Drug Disco, King Of Prussia, PA USA
关键词
antioxidant; carvedilol; hypertension; oxidative stress; OXYGEN SPECIES GENERATION; CHRONIC HEART-FAILURE; LOW-DENSITY-LIPOPROTEIN; NADPH OXIDASE ACTIVITY; OXIDATIVE STRESS; IN-VITRO; ENDOTHELIAL DYSFUNCTION; SUPEROXIDE-PRODUCTION; DIABETIC NEPHROPATHY; MONONUCLEAR-CELLS;
D O I
10.1097/HJH.0b013e3280127948
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Oxidative and inflammatory stresses are cardinal in the pathogenesis of hypertension and atherosclerosis. Oxidative stress also leads to the induction of inflammation through the activation of proinflammatory transcription factors. Understanding the mechanisms leading to oxidative stress and the means of suppressing it are important in controlling complications related to atherogenesis, since oxidative and inflammatory stress are important in the pathogenesis of atherosclerosis. The failure of chemical antioxidants [ which scavenge reactive oxygen species ( ROS)], such as vitamins E and C, has led to further exploration of the ROS- suppressive effects of drugs used in the treatment of cardiovascular disease. Carvedilol has been shown to possess both ROS- scavenging and ROS- suppressive effects, and its use is associated with a reduction in oxidative stress. Furthermore, anti-inflammatory effects of carvedilol have now been described. Although further clinical investigations are required, these properties may contribute to the improvement in clinical
引用
收藏
页码:731 / 741
页数:11
相关论文
共 84 条
  • [1] Antioxidant properties of carvedilol and metoprolol in heart failure: A double-blind randomized controlled trial
    Arumanayagam, M
    Chan, S
    Tong, S
    Sanderson, JE
    [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2001, 37 (01) : 48 - 54
  • [2] Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension - A randomized controlled trial
    Bakris, GL
    Fonseca, V
    Katholi, RE
    McGill, JB
    Messerli, FH
    Phillips, RA
    Raskin, P
    Wright, JT
    Oakes, R
    Lukas, MA
    Anderson, KM
    Bell, DSH
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (18): : 2227 - 2236
  • [3] Importance of nitric oxide in the control of renal hemodynamics
    Baylis, C
    Qiu, CB
    [J]. KIDNEY INTERNATIONAL, 1996, 49 (06) : 1727 - 1731
  • [4] Book Wendy M, 2002, Congest Heart Fail, V8, P173, DOI 10.1111/j.1527-5299.2002.00718.x
  • [5] BOOK WM, 2002, CONGEST HEART FAIL, V8, P190
  • [6] SB211475, a metabolite of carvedilol, reduces infarct size after myocardial ischemic and reperfusion injury in rabbits
    Brunvand, H
    Liu, GL
    Ma, XL
    Yue, TL
    Ruffolo, RR
    Feuerstein, GZ
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 356 (2-3) : 193 - 198
  • [7] Byrne JA, 2003, ARCH MAL COEUR VAISS, V96, P214
  • [8] Endothelial dysfunction in cardiovascular diseases - The role of oxidant stress
    Cai, H
    Harrison, DG
    [J]. CIRCULATION RESEARCH, 2000, 87 (10) : 840 - 844
  • [9] Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy
    Cappola, TP
    Kass, DA
    Nelson, GS
    Berger, RD
    Rosas, GO
    Kobeissi, ZA
    Marbán, E
    Hare, JM
    [J]. CIRCULATION, 2001, 104 (20) : 2407 - 2411
  • [10] Cheng JH, 2001, CARDIOVASC DRUG REV, V19, P152